Anticholinergic / Antimuscarinic Agents
Anticholinergic medications (antimuscarinics) are a cornerstone of urologic pharmacotherapy, primarily for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD).[1][2] They block muscarinic receptors (M2 and M3) in the detrusor muscle, inhibiting involuntary contractions, increasing bladder capacity, and reducing urgency and frequency.
The class has six FDA-approved agents with broadly similar efficacy but meaningfully different tolerability, CNS penetration, and dementia-risk profiles. The 2022 SUFU White Paper on anticholinergics and dementia risk and the 2024 AUA/SUFU OAB guideline together have shifted contemporary practice toward β3-agonist-first positioning for many OAB patients, with anticholinergics reserved for specific indications, combination therapy, or patient-specific factors.
Mechanism of Action
- M3 receptors produce direct detrusor smooth muscle contraction via extracellular calcium entry (L-type channels) + Rho kinase activation
- M2 receptors (more numerous) facilitate M3-mediated contractions and can reverse β-adrenoceptor-mediated relaxation[3][4]
- Antagonism of M3 → inhibition of detrusor contraction → increased bladder capacity + reduced urgency
- Off-target effects at other muscarinic receptor populations → the class side-effect profile
Receptor selectivity
- M3-selective: darifenacin, solifenacin
- Non-selective (M1–M5): oxybutynin, tolterodine, trospium, fesoterodine
- Non-selective agents cause broader side effects (salivary glands, CNS, heart, gut)[3][5]
CNS penetration — the mechanism behind dementia risk
- High CNS penetration: oxybutynin (lipophilic, non-selective)
- Lower CNS penetration: solifenacin, darifenacin, tolterodine
- Minimal CNS penetration: trospium (quaternary amine — poorly crosses BBB)[3][6]
This gradient predicts cognitive side-effect burden and — with chronic exposure — dementia risk.
FDA-Approved Agents
Six anticholinergic medications are FDA-approved for OAB in the United States.[2]
| Agent | Receptor selectivity | CNS penetration | Typical dose | Distinguishing feature |
|---|---|---|---|---|
| Oxybutynin (IR, ER, TD patch, topical gel) | Non-selective | High | IR: 5 mg TID; ER: 5–30 mg daily; patch 3.9 mg twice weekly | Oldest; most extensive evidence; highest dementia concern; transdermal avoids first-pass metabolism and reduces systemic side effects |
| Tolterodine (IR, ER) | Non-selective | Moderate | IR: 2 mg BID; ER: 4 mg daily | Workhorse; less dry mouth than IR oxybutynin |
| Fesoterodine | Non-selective (prodrug → active 5-HMT) | Moderate | 4 mg or 8 mg daily | Active metabolite of tolterodine; flexible dosing |
| Solifenacin | M3-selective | Moderate | 5 mg or 10 mg daily | Better QoL + efficacy vs. tolterodine in head-to-head; widely used |
| Darifenacin | M3-selective | Lower | 7.5 mg or 15 mg daily | M3 selectivity in theory reduces CNS side effects |
| Trospium (IR, ER) | Non-selective | Minimal (quaternary amine) | IR: 20 mg BID; ER: 60 mg daily | Poor BBB penetration → minimal cognitive risk; preferred in elderly and cognitively impaired |
International agents not available in the US include imidafenacin, propiverine, and propantheline.[1][3]
Clinical Efficacy
Vs. Placebo (Cochrane 2023, 104 trials, 47,106 patients)[1]
| Outcome | Effect vs. placebo |
|---|---|
| Micturition frequency | –0.85 episodes / 24 hr (95% CI 0.73–0.98 lower) |
| Urgency episodes | –0.85 episodes / 24 hr (95% CI 0.67–1.03 lower) |
| Patient-reported cure/improvement | RR 1.38 (95% CI 1.15–1.66) |
| Quality of life | MD −4.41 (on −100 to 0 scale) |
| Withdrawal due to AEs | RR 1.37 vs. placebo |
Class efficacy
- All anticholinergics reduce urinary frequency by ~2–4 voids per day
- Reduce incontinence by 10–20 episodes per week
- FDA regulatory trials show 53–80% reduction in incontinence episodes; 12–32% reduction in frequency[2]
- Placebo response is substantial (30–47% for incontinence) — a durable reminder that behavioral therapy and regression-to-mean matter
Head-to-head comparisons[7][8]
Solifenacin vs. IR tolterodine — solifenacin superior:
- Quality of life (SMD −0.12)
- Patient-reported cure/improvement (RR 1.25)
- Leakage (WMD −0.30)
- Urgency episodes (WMD −0.43)
- Less dry mouth than IR tolterodine
Fesoterodine 8 mg vs. ER tolterodine — fesoterodine superior for all efficacy endpoints, but higher withdrawal (RR 1.45) and higher dry mouth (RR 1.80)
Tolterodine vs. oxybutynin — similar efficacy, tolterodine has less dry mouth (RR 0.52 for AE-driven withdrawal)
Extended-release > immediate-release — similar efficacy, significantly less dry mouth in ER formulations
Dose comparisons
- Tolterodine 1/2/4 mg: similar efficacy; higher dose → more dry mouth
- Solifenacin 5 vs. 10 mg: 10 mg more effective but more dry mouth
Adverse Effects
Common anticholinergic burden[1][2]
| AE | Rate / relative risk |
|---|---|
| Dry mouth | Most common; up to 70%; RR 3.50 vs. placebo |
| Constipation | Common; dose-dependent |
| Dry eyes | Frequent |
| Blurred vision | Less common |
| Urinary retention | RR 3.52 vs. placebo (~1% absolute risk) |
| Withdrawal due to AEs | RR 1.37 vs. placebo |
Cognitive impairment and dementia risk
The most consequential modern controversy in OAB pharmacotherapy:[9][10][11]
French case-control study (4,810 cases, 24,050 controls): OAB anticholinergic use → OR 1.23 for dementia, with clear dose-response relationship:
| Cumulative exposure | OR for dementia |
|---|---|
| 1–90 DDDs | 1.07 |
| 91–365 DDDs | 1.29 |
| >365 DDDs | 1.48 |
Agent-specific signal:
Other series: 7 observational studies reported 10–65% increased dementia risk across the class, though effect size and confounding varied.[6]
2022 SUFU White Paper conclusions[11]
- Chronic use (>3 months) likely associated with increased dementia risk
- Short-term use (<3 months) — unclear impact
- Dose–response relationship supports the causal direction
- Trospium is the lowest-risk anticholinergic for cognitive side effects
- Patients should be counseled about the dementia association before long-term initiation
- Alternatives (β3-agonists, botulinum toxin, neuromodulation) should be considered especially in elderly and cognitively-vulnerable patients
Mechanism
Anticholinergic blockade of acetylcholine in the brain disrupts cholinergic neurotransmission critical for learning and memory. Agents with greater CNS penetration (oxybutynin) pose higher cognitive risk than those with limited CNS penetration (trospium).[3][12]
However, one propensity-matched cohort study (782 pairs) found no association with cognitive decline, reminding us that the signal is not bulletproof and that residual confounding in observational studies remains a concern.[6]
Contraindications and Precautions
Absolute contraindications[2][6][13]
- Untreated narrow-angle glaucoma (uncommon but established)
- Gastric retention / severe GI obstructive disorders
- Urinary retention (relative → absolute depending on severity)
Use with caution
| Situation | Consideration |
|---|---|
| PVR > 150 mL | Increased risk of urinary retention; consider alternative |
| Significant BPH | May worsen obstructive symptoms; use with α-blocker if chosen |
| Cardiac arrhythmia | Can exacerbate tachyarrhythmias |
| GI motility disorders | Ulcerative colitis, intestinal atony, myasthenia gravis |
| Renal impairment | Particularly for renally excreted agents (trospium) |
| Elderly | Higher risk of cognitive effects, falls, constipation |
| Parkinson's / MS / scleroderma / hypothyroidism | Conditions affecting motility and cognition |
AUA/SUFU guidelines[14]
- Discuss dementia risk with patients taking or about to be prescribed antimuscarinics
- Use with extreme caution in narrow-angle glaucoma, impaired gastric emptying, or history of urinary retention
- Obtain PVR if retention history / risk
- Re-assess 4–8 weeks after initiation for efficacy and side effects
Clinical Positioning
Contemporary paradigm
2024 AUA/SUFU OAB guideline positions pharmacotherapy as:[14]
- Behavioral therapy first (pelvic-floor training, fluid management, bladder retraining)
- Pharmacotherapy: β3-agonist or antimuscarinic — with β3-agonist slightly preferred for better tolerability and no dementia signal
- Combination therapy (β3-agonist + antimuscarinic) for suboptimal response
- Third-line: botulinum toxin, sacral neuromodulation, PTNS
When to choose antimuscarinic over β3-agonist
- Patient has tried β3-agonist without adequate response
- Combination therapy — synergistic effect in patients with suboptimal monotherapy
- Patient preference / cost (antimuscarinics are generic and cheaper)
- Specific subpopulations where antimuscarinic evidence is stronger (NLUTD, pediatric)
When to avoid anticholinergics
- Elderly patient with cognitive concerns — use β3-agonist or trospium
- Active cognitive impairment / dementia — avoid entirely
- Severe BPH with high PVR — worsens retention
- Narrow-angle glaucoma
Adherence
Long-term adherence is suboptimal — most studies show persistence <50% at 12 months.[2] Drivers of discontinuation: dry mouth, constipation, cognitive side effects, inadequate efficacy.
Combination Therapy
Antimuscarinic + β3-agonist (e.g., solifenacin 5 mg + mirabegron 25–50 mg) provides superior efficacy vs. monotherapy in patients with partial response — the BESIDE and SYNERGY trials established this.[15][16]
- Additional frequency reduction over monotherapy
- Additional urgency/incontinence reduction
- Increased anticholinergic side effects vs. β3-agonist alone — so the choice is a trade-off
Special Populations
Neurogenic Lower Urinary Tract Dysfunction (NLUTD)
Antimuscarinics are first-line pharmacotherapy for bladder storage dysfunction in NLUTD:[17][18][19]
- Reliably increase maximum cystometric capacity and voided / catheterized volumes
- Decrease detrusor pressure
- Improve urgency and incontinence across SCI, MS, spina bifida
- No consistent evidence of superiority among agents
- May be combined with β3-agonists or α-blockers
- Intravesical oxybutynin — delivers the drug locally with reduced systemic absorption; a valuable option in CIC-dependent NLUTD patients with systemic intolerance
Pediatric neurogenic bladder
Oxybutynin is the most-used agent — effective at increasing capacity, lowering storage pressures, abolishing overactive contractions. Mirabegron and (rarely) gabapentin are alternatives in intolerant patients.[20]
Men with BPH
Antimuscarinics may benefit men with predominantly storage symptoms, typically combined with an α-blocker. Monotherapy evidence is lacking. Combination therapy (α-blocker + antimuscarinic) achieves synergy. Check PVR before initiation and at follow-up.[21][22]
Formulations
| Formulation | Advantages | Notes |
|---|---|---|
| Extended-release oral | Less dry mouth than IR; QD dosing | Default for most agents |
| Immediate-release oral | Faster onset; cheapest | Higher dry mouth burden |
| Transdermal patch (oxybutynin) | Bypasses first-pass metabolism; less dry mouth | Skin reactions in some patients |
| Topical gel (oxybutynin) | Application flexibility | Transfer risk to partner / children |
| Intravesical instillation (oxybutynin) | Minimal systemic absorption | NLUTD / CIC patients with systemic intolerance |
Progression to Advanced Therapies
When OAB does not respond adequately to anticholinergics + β3-agonists (as monotherapy or combined), third-line therapies should be considered:[14][23]
- Intradetrusor onabotulinumtoxinA (100 U for idiopathic OAB; 200 U for NLUTD)
- Sacral neuromodulation (InterStim, Axonics)
- Posterior tibial nerve stimulation (PTNS, eCoin, Revi)
See Also
- β3-adrenergic agonists — companion pharmacologic class
- Desmopressin — for nocturnal polyuria
- Storage & OAB overview
- Neuromodulation devices
References
1. Stoniute A, Madhuvrata P, Still M, et al. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5:CD003781. doi:10.1002/14651858.CD003781.pub3
2. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. doi:10.1001/jama.2017.12137
3. Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130–148. doi:10.1016/j.pharmthera.2018.04.010
4. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147 Suppl 2:S80–7. doi:10.1038/sj.bjp.0706560
5. Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57. doi:10.1056/NEJMcp1106637
6. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809–821. doi:10.1001/jama.2025.7045
7. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429. doi:10.1002/14651858.CD005429.pub2
8. Nazir J, Kelleher C, Aballéa S, et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis. Neurourol Urodyn. 2018;37(3):986–996. doi:10.1002/nau.23413
9. Malcher MF, Droupy S, Berr C, et al. Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French National Medical-Administrative Database. J Urol. 2022;208(4):863–871. doi:10.1097/JU.0000000000002804
10. Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment. Urology. 2024;186:123–129. doi:10.1016/j.urology.2023.11.033
11. Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928–1933. doi:10.1002/nau.25037
12. Taylor-Rowan M, Alharthi AA, Noel-Storr AH, et al. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults. Cochrane Database Syst Rev. 2023;12:CD015405. doi:10.1002/14651858.CD015405.pub2
13. Food and Drug Administration. Trospium chloride prescribing information. Updated 2025-12-30.
14. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11–20. doi:10.1097/JU.0000000000003985
15. Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333. doi:10.1016/j.eururo.2018.03.020
16. Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025. doi:10.1007/s00228-025-03855-1
17. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239
18. Hamouda A, Covarrubias C, Campeau L. Advancing personalized care for neurogenic bladder — what medical management should be first line for bladder storage symptoms in NLUTD: pro anticholinergic. Neurourol Urodyn. 2025. doi:10.1002/nau.70177
19. Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263(12):2555–2564. doi:10.1007/s00415-016-8212-2
20. Diamond DA, Chan IHY, Holland AJA, et al. Advances in paediatric urology. Lancet. 2017;390(10099):1061–1071. doi:10.1016/S0140-6736(17)32282-1
21. Pang R, Zhou XY, Wang X, et al. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. Cochrane Database Syst Rev. 2021;2:CD012336. doi:10.1002/14651858.CD012336.pub2
22. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. J Urol. 2024;211(1):11–19. doi:10.1097/JU.0000000000003698
23. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. Expert Opin Pharmacother. 2023;24(18):2005–2019. doi:10.1080/14656566.2023.2264183